We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · September 28, 2020

Clinical Outcomes of Patients With Breast Cancer Relapsing After (Neo)adjuvant Trastuzumab and Receiving Trastuzumab Rechallenge or Lapatinib-Based Therapy

ESMO open

 

Additional Info

ESMO open
Clinical Outcomes of Patients With Breast Cancer Relapsing After (Neo)adjuvant Trastuzumab and Receiving Trastuzumab Rechallenge or Lapatinib-Based Therapy: A Multicentre Retrospective Cohort Study
ESMO Open 2020 Aug 01;5(4)1, E Blondeaux, AR Ferreira, F Poggio, F Puglisi, C Bighin, F Sottotetti, F Montemurro, E Poletto, A Lai, V Sini, G Minuti, S Mura, A Fontana, P Fregatti, B Cardinali, M Lambertini, L Del Mastro

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading